Stock BALAXI BALAXI PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Balaxi Pharmaceuticals Limited

Equities

BALAXI

INE618N01022

Pharmaceuticals

Delayed NSE India S.E.
Other stock markets
 06:18:15 2024-06-06 am EDT 		5-day change 1st Jan Change
106.5 INR -0.56% Intraday chart for Balaxi Pharmaceuticals Limited -18.86% +23.16%
May. 29 Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
May. 09 Balaxi Pharmaceuticals Limited Appoints Mahesh Inani as the Compliance Officer CI

Valuation

Fiscal Period: March 2017 2018 2019 2020 2021 2022
Capitalization 1 54.42 44.99 115.5 740 5,245 3,516
Enterprise Value (EV) 1 31.4 28.53 114.2 700 5,265 3,479
P/E ratio -6.89 x -5.84 x 5.88 x 9.12 x 13.8 x 7.38 x
Yield - - - - - 0.14%
Capitalization / Revenue -8.88 x - 0.83 x 1.56 x 2.27 x 1.26 x
EV / Revenue -5.13 x - 0.82 x 1.48 x 2.28 x 1.25 x
EV / EBITDA -4.2 x -3.73 x 5.3 x 8.41 x 12.4 x 6.93 x
EV / FCF -6.4 x -7.1 x -6.19 x -4.81 x -40.5 x 26.3 x
FCF Yield -15.6% -14.1% -16.2% -20.8% -2.47% 3.81%
Price to Book 2.31 x 2.89 x 3.28 x 2.67 x 8.07 x 3.11 x
Nbr of stocks (in thousands) 15,200 15,200 15,200 50,000 50,000 50,000
Reference price 2 3.580 2.960 7.600 14.80 104.9 70.32
Announcement Date 9/12/17 8/20/18 8/31/19 8/19/20 7/17/21 5/23/22
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2017 2018 2019 2020 2021 2022
Net sales 1 -6.125 - 139.8 473.6 2,313 2,794
EBITDA 1 -7.476 -7.659 21.54 83.21 425.9 501.8
EBIT 1 -7.484 -7.678 21.51 83.13 422.9 497.2
Operating Margin 122.18% - 15.39% 17.55% 18.28% 17.8%
Earnings before Tax (EBT) 1 -7.896 -7.699 24.39 88.74 443.3 545.2
Net income 1 -7.896 -7.699 19.66 61.04 381.4 476.6
Net margin 128.9% - 14.07% 12.89% 16.49% 17.06%
EPS 2 -0.5194 -0.5065 1.293 1.623 7.627 9.532
Free Cash Flow 1 -4.906 -4.021 -18.46 -145.6 -129.9 132.5
FCF margin 80.1% - -13.21% -30.74% -5.61% 4.74%
FCF Conversion (EBITDA) - - - - - 26.4%
FCF Conversion (Net income) - - - - - 27.8%
Dividend per Share - - - - - 0.1000
Announcement Date 9/12/17 8/20/18 8/31/19 8/19/20 7/17/21 5/23/22
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - 19.9 -
Net Cash position 1 23 16.5 1.33 40 - 37.4
Leverage (Debt/EBITDA) - - - - 0.0467 x -
Free Cash Flow 1 -4.91 -4.02 -18.5 -146 -130 133
ROE (net income / shareholders' equity) -28.7% -39.7% 77.5% 39% 82.3% 53.5%
ROA (Net income/ Total Assets) -15.2% -23.7% 34.5% 24.7% 39% 22.5%
Assets 1 51.88 32.54 57 247.2 978.6 2,118
Book Value Per Share 2 1.550 1.020 2.320 5.550 13.00 22.60
Cash Flow per Share 2 1.520 1.080 0.0900 0.8000 0.3300 1.440
Capex - 0.11 0.05 1.83 12.8 53.2
Capex / Sales - - 0.04% 0.39% 0.55% 1.9%
Announcement Date 9/12/17 8/20/18 8/31/19 8/19/20 7/17/21 5/23/22
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
BALAXI PHARMACEUTICALS LIMITED Stock Balaxi Pharmaceuticals Limited
+23.16% 65.23M
MCKESSON CORPORATION Stock McKesson Corporation
+25.19% 75.34B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-2.82% 23.86B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+8.07% 8.61B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+10.64% 8.52B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-22.31% 7.78B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+12.09% 5.18B
GALENICA AG Stock Galenica AG
+2.96% 4.13B
EBOS GROUP LIMITED Stock EBOS Group Limited
-5.04% 4.03B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+3.71% 3.82B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. BALAXI Stock
  4. Financials Balaxi Pharmaceuticals Limited